Browse the evidence

Chronic hyperglycemia induces oxidative stress via multiple metabolic pathways (polyol, AGE, PKC, hexosamine), which directly causes insulin resistance and beta-cell dysfunction, leading to Type 2 Diabetes.

Managing blood sugar levels is critical not just for immediate comfort, but to prevent the cellular oxidative stress that drives long-term complications like nerve and kidney damage. Focus on dietary strategies that minimize glucose spikes to reduce the metabolic burden on your cells.

The gut bacterium Eubacterium rectale causally decreases plasma levels of hydrogen sulfite, a toxin that negatively affects cardiovascular function.

Maintaining a healthy gut microbiome, specifically by supporting bacteria like Eubacterium rectale, may help reduce hydrogen sulfite levels in your blood, which is beneficial for cardiovascular health.

Age-related insulin resistance in older adults is primarily driven by increased visceral adiposity and central fat distribution rather than aging itself, as accounting for body fat and distribution eliminates age as a predictor of insulin action.

Focus on maintaining a healthy body weight and minimizing visceral fat through diet and exercise. This is more critical for metabolic health in older age than simply accepting 'aging' as the cause of metabolic issues.

Global efforts to reduce malnutrition have been more than offset by a rapidly rising obesity burden, resulting in a widening 'double burden' of disease where obesity-related disability-adjusted life years (DALYs) now vastly exceed malnutrition-related DALYs.

Global health strategies must stop treating hunger and obesity as separate issues. As countries develop and reduce starvation, they often swing into obesity epidemics. Effective policy requires a unified approach that ensures food security while simultaneously preventing the shift toward unhealthy, obesity-driving diets, particularly in low-to-middle income regions undergoing rapid economic change.

Obesity-related mortality and DALYs are highest in low-to-middle Socio-Demographic Index (SDI) countries, whereas malnutrition burden is concentrated in low SDI countries, creating a distinct geographic and socioeconomic split in the double burden of disease.

Public health in developing nations must anticipate the 'nutrition transition.' As economies grow, access to food increases, but often shifts toward unhealthy, obesity-driving diets. Policies must simultaneously address undernutrition and prevent the rise of obesity, as the burden of obesity-related death peaks in middle-income countries, not the wealthiest ones.

Aging adipose tissue undergoes early structural and functional decline, characterized by visceral fat redistribution, loss of brown/beige fat, and accumulation of senescent cells, which drives systemic metabolic dysfunction and accelerates aging.

Your fat cells are not just storage; they are active organs that signal your body's health status. As you age, these signals can become harmful, leading to inflammation and metabolic issues. Maintaining healthy adipose tissue through balanced nutrition and activity is crucial for slowing down age-related decline.

Intermittent administration of the senolytic drug combination dasatinib and quercetin (D&Q) reduces senescence and inflammation in adipose tissue, leading to improved systemic metabolic function (fasting glucose, glucose tolerance, and lipid profiles) in old age.

For older adults, intermittent treatment with dasatinib and quercetin may improve metabolic health by clearing senescent cells from fat tissue, reducing inflammation, and improving glucose tolerance. This suggests that targeting cellular aging could be a viable strategy for managing age-related metabolic decline.

Chronic systemic inflammation drives skeletal muscle atrophy by directly activating pro-catabolic signaling pathways (NF-κB, JAK/STAT, p38MAPK) that increase protein degradation via UPS/ALP and inhibit protein synthesis via IGF-1/Akt/mTOR suppression.

If you are experiencing muscle loss alongside a chronic inflammatory condition (like autoimmune disease, diabetes, or chronic infection), standard resistance training and high protein intake may be insufficient on their own. Medical management of the underlying inflammation is critical to stop the biological signals that actively break down muscle tissue.

Inflammation indirectly causes muscle atrophy by dysregulating the Hypothalamic-Pituitary-Adrenal (HPA) axis, leading to excessive glucocorticoid release, which further inhibits muscle protein synthesis and promotes proteolysis.

Managing stress and underlying inflammation is crucial because chronic stress and inflammation can trigger hormonal responses (cortisol) that actively break down muscle. Medical interventions that stabilize the HPA axis or reduce inflammatory cytokines may help preserve muscle mass.

Myostatin (MSTN) levels are increased by inflammatory factors (TNF-α, IL-6) and act as a negative regulator of muscle mass by activating the Smad2/3 pathway, which upregulates E3 ubiquitin ligases (MuRF1, Atrogin-1) and inhibits satellite cell recruitment.

High levels of inflammatory cytokines can increase Myostatin, a protein that naturally limits muscle growth. In chronic disease, this system is overactive, contributing to muscle loss. Therapies targeting Myostatin or its receptors are being investigated to counteract this loss.

Mitochondrial dysfunction acts as a primary driver of skeletal muscle atrophy by triggering catabolic signaling pathways that promote the expression of muscle atrophy genes and increasing oxidative stress.

To support muscle mass, prioritize activities that improve mitochondrial health, such as regular aerobic and resistance exercise. These interventions help regulate mitochondrial function and may prevent or treat muscle atrophy, especially in aging or diseased states.

GLP-1 receptor agonists (GLP-1RAs) exert anti-inflammatory effects by suppressing pro-inflammatory cytokine production (TNF-α, IL-6, IL-1β) and inhibiting the NF-κB pathway, independent of glycemic control.

GLP-1 medications like semaglutide and liraglutide do more than just lower blood sugar; they actively reduce systemic inflammation by blocking key inflammatory pathways (NF-κB) and lowering pro-inflammatory cytokines. This benefit exists regardless of whether your blood sugar improves, suggesting these drugs may help with inflammatory conditions beyond diabetes.

Obesity induces low-grade chronic inflammation in white adipose tissue (WAT) via adipocyte death (apoptosis/necroptosis), which recruits pro-inflammatory macrophages (forming crown-like structures) and triggers systemic insulin resistance and metabolic syndrome.

Obesity is not just about storing fat; it is an active inflammatory state. Excess fat, especially visceral fat, leads to adipocyte death, which triggers an immune response (inflammation) that blocks insulin signaling. To improve metabolic health, strategies must address this underlying inflammation, not just caloric intake, by supporting adipose tissue health and reducing cytokine-driven resistance.

TNF and NF-κB signaling pathways directly inhibit insulin signaling by phosphorylating IRS-1, thereby causing insulin resistance; neutralizing TNF or inhibiting IKKβ improves glucose homeostasis.

Chronic inflammation in fat tissue directly blocks insulin's ability to work by interfering with key signaling proteins (IRS-1). Reducing this inflammation, whether through weight loss, exercise, or potentially anti-inflammatory strategies, can restore insulin sensitivity.

Plant-based meat alternatives offer environmental benefits over animal meat, including reduced greenhouse gas emissions, land use, and water use, although life cycle assessments vary based on production methods and energy sources.

Switching to plant-based meat alternatives generally reduces your environmental footprint, including greenhouse gas emissions, land use, and water consumption. However, the exact benefit depends on the specific product and its production methods.

Mid-day time-restricted feeding (mTRF), defined as an 8-hour eating window between 11:00 and 20:00, does not significantly improve insulin sensitivity, fasting glucose, body mass, or inflammation compared to ad libitum eating in healthy non-obese adults.

If you prefer eating later in the day (e.g., 11 AM to 7 PM), be aware that this specific mid-day TRF window may not improve insulin sensitivity, reduce body weight, or lower inflammation compared to normal eating habits in healthy, non-obese individuals. If metabolic health is your goal, shifting your eating window to end earlier (by 3 PM) may be more effective.

Obese gut microbiota reduces the capacity to metabolize ethanolamine, leading to its accumulation in the gut, which triggers a molecular cascade (ARID3a/miR-101a-3p/Zo1) that weakens intestinal barriers, causing leaky gut, systemic inflammation, and glucose metabolic dysfunction.

If you are obese or have type 2 diabetes, your gut microbiome may be failing to break down ethanolamine, leading to gut leakiness and inflammation. Supporting your gut with probiotics that specifically metabolize ethanolamine may help restore gut barrier function and improve metabolic health. Focus on dietary patterns that support a diverse microbiome.

Gut-derived GLP-1 signaling via vagal afferents regulates hepatic glucose production and postprandial glycemia, independent of direct pancreatic insulin secretion.

If you are managing blood sugar, understand that GLP-1 agonists (like Ozempic or Trulicity) do more than just trigger insulin. They send signals to your brain and liver to reduce the amount of sugar your liver releases into your blood. This neural pathway is a key reason these drugs are effective for glucose control, even if your pancreas function is declining.

Dietary fiber interventions in healthy adults do not consistently produce significant increases in total or individual short-chain fatty acid (SCFA) levels, with outcomes strictly dependent on fiber type, dose, and analytical methodology.

Do not assume that taking a generic fiber supplement will automatically boost your short-chain fatty acids. The effect is highly variable and depends on the specific type of fiber (e.g., inulin vs. resistant starch), the dose, and your individual gut microbiome composition. Focus on diverse fiber sources from whole foods rather than expecting a uniform metabolic boost from supplements.

The analytical method used to measure SCFAs (e.g., GC vs. HPLC) significantly influences the detection of statistically significant changes, with GC-based methods on plasma/serum showing more frequent significant changes than HPLC on feces.

When evaluating fiber studies, check the measurement method. Studies using Gas Chromatography (GC) on blood samples are more likely to report significant SCFA changes than those using HPLC on feces, even if the biological effect is similar. This highlights the difficulty in measuring blood SCFAs due to low concentrations.

In heart failure with reduced ejection fraction (HFrEF), higher adiposity measured by waist-to-height ratio is associated with a significantly higher risk of heart failure hospitalization, and the 'obesity-survival paradox' (where higher BMI appeared protective) is eliminated when adjusting for natriuretic peptides and other prognostic variables.

For patients with heart failure and reduced ejection fraction, relying on BMI to assess risk is misleading. Higher waist-to-height ratio (indicating central adiposity) is linked to a significantly higher risk of hospitalization. The idea that being 'overweight' is protective in heart failure is a statistical artifact; once you account for fluid retention and biomarkers like natriuretic peptides, higher adiposity clearly increases risk. Focus on healthy body composition rather than just scale weight.

Obesity-induced infiltration of M1 macrophages into metabolic tissues (adipose, liver, muscle) drives chronic inflammation that directly causes insulin resistance by interfering with insulin signaling pathways.

For those with obesity, reducing the inflammatory burden on metabolic tissues is key. This involves strategies that reduce macrophage infiltration, such as weight loss and potentially anti-inflammatory dietary patterns, to improve insulin sensitivity.

Specific inflammatory pathways (JNK, IKK/NF-κB, JAK/STAT) activated by macrophage-derived cytokines (TNF-α, IL-6, IL-1β) directly impair insulin signaling by causing serine phosphorylation of IRS-1.

Understanding that inflammation directly blocks insulin action at the cellular level highlights why anti-inflammatory strategies (like weight loss) are effective for improving insulin sensitivity.

Genetic predisposition for higher leisure screen time (LST) and lower moderate-to-vigorous physical activity (MVPA) causally increases body mass index (BMI) and adiposity, and these protective effects of physical activity on disease risk are mediated or confounded by BMI.

This research suggests that the health benefits of reducing sedentary time and increasing physical activity are largely achieved through their effect on body weight and fat. To prevent diseases like type 2 diabetes and heart disease, managing body mass index is likely a key mechanism through which physical activity works.